Neurokinin-1 enables measles virus trans-synaptic spread in neurons  by Makhortova, Nina R. et al.
7) 235–244
www.elsevier.com/locate/yviroVirology 362 (200Neurokinin-1 enables measles virus trans-synaptic spread in neurons
Nina R. Makhortova a, Peter Askovich a,1, Catherine E. Patterson a,2, Lisa A. Gechman a,
Norma P. Gerard b, Glenn F. Rall a,⁎
a Division of Basic Science, The Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
b Children’s Hospital, Perlmutter Laboratory, Boston, MA 02115, USA
Received 19 December 2006; returned to author for revision 19 January 2007; accepted 22 February 2007
Available online 16 April 2007Abstract
Measles virus (MV), a morbillivirus that remains a significant human pathogen, can infect the central nervous system, resulting in rare but
often fatal diseases, such as subacute sclerosing panencephalitis. Previous work demonstrated that MV was transmitted trans-synaptically and that,
while a cellular receptor for the hemagglutinin (H) protein was required for MV entry, it was dispensable for subsequent cell-to-cell spread. Here,
we explored what role the other envelope protein, fusion (F), played in trans-synaptic transport. We made the following observations: (1) MV-F
expression in infected neurons was similar to that seen in infected fibroblasts; (2) fusion inhibitory peptide (FIP), an inhibitor of MV fusion,
prevented both infection and spread in primary neurons; (3) Substance P, a neurotransmitter with the same active site as FIP, also blocked neuronal
MV spread; and (4) both genetic deletion and pharmacological inhibition of the Substance P receptor, neurokinin-1 (NK-1), reduced infection of
susceptible mice. Together, these data implicate a role for NK-1 in MV CNS infection and spread, perhaps serving as an MV-F receptor or co-
receptor on neurons.
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Neurokinin-1Introduction
In rare cases, MV can invade and persist within the human
central nervous system (CNS), leading to progressive and fatal
neurological diseases, including subacute sclerosing panence-
phalitis (SSPE) (Anlar, 1997; Griffin and Bellini, 1996;
Schneider-Schaulies et al., 1999). Two hallmarks of SSPE are
the protracted period between initial infection and signs of
disease (often years), and the inability to recover infectiousAbbreviations: MV, measles virus; CNS, central nervous system; dpi, days
post-infection; hpi, hours post-infection; NK-1, neurokinin-1; F, fusion; H,
hemagglutinin; NSE, neuron-specific enolase.
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doi:10.1016/j.virol.2007.02.033virus from affected brain tissues, despite the extensive presence
of MV RNA and protein (Katz, 1995; Payne et al., 1969). This
is in contrast to the rapid and highly productive infections that
occur in non-CNS tissues. The apparent differences in MV
replication and spread within the human CNS implied that viral
neurotransmission was substantively less cytopathic and
productive than in non-neuronal tissues.
Mice are normally non-permissive for MV; thus, to study MV
spread and pathogenesis in the CNS, a transgenic mouse model of
neuronal infection was developed. These transgenic mice
expressed CD46, the first identified human MV receptor (Dorig
et al., 1993; Naniche et al., 1993), now thought to be the primary
receptor for vaccine strains (Cattaneo, 2004), under the transcrip-
tional control of the neuron-specific promoter, neuron-specific
enolase (NSE) (Rall et al., 1997). Subsequent challenge of NSE-
CD46 transgenic mice with the vaccine strain, MV-Edmonston,
by either the intracerebral or intranasal route resulted in infection
in all transgenic mice. While adult immunocompetent mice re-
solved the infection, both CD46+ neonates and immunodeficient
Fig. 1. MV F expression in infected neurons. 48 hpi with MV-Ed (MOI=3),
primary CD46+ neurons and Vero cells were fixed for immunostaining or
solubilized in protein sample buffer as described. The percent of infected cells
was determined by immunochemistry, after which the protein lysate volume
equivalent to 105 infected cells was then subjected toWestern blot analysis using
an anti-F antibody. Size standards are indicated at the right. Shown is one
representative experiment of three.
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disease resulting from unrestricted neuronal infection (Lawrence
et al., 1999; Rall et al., 1997).
Using primary hippocampal neurons obtained from NSE-
CD46+ embryos, we showed that MV neuronal infection was
noncytopathic and did not result in release of extracellular
progeny, despite extensive viral spread (Lawrence et al., 2000).
Interestingly, neuron-to-neuron spread of MV occurred exclu-
sively at the synapse and did not require expression of CD46
(Lawrence et al., 2000; Oldstone et al., 1999; Rall et al., 1997),
indicating that a hemagglutinin (H)–receptor interaction may
not be required at the synaptic interface (Lawrence et al., 2000).
Based on this observation, we next wanted to establish what
role, if any, the viral fusion protein played in trans-synaptic
transport. While it is generally believed that H and F have
interaction domains that coordinate receptor binding and fusion
(Hu et al., 1992), work by other laboratories has suggested that
F may act independently of H and may even govern target cell
specificity. For example, in simian virus 5 (SV5), F promotes
fusion in the absence of the hemagglutinin-neuraminidase (HN)
protein, albeit less efficiently than when HN is present (Horvath
et al., 1992; Ito et al., 1997). Moreover, SV5 F protein mutants
that require SV5 HN for fusion at 37 °C can fuse in an HN-
independent manner at higher temperatures. Thus, fusion may
require surmounting a thermodynamic threshold, which can be
accomplished by a conformational change in the HN protein,
increased temperature, or perhaps interaction of the F protein
with its own cellular receptor (Dutch et al., 2001; Paterson et al.,
2000). This final possibility has support in the literature since
the F2 fusion protein of respiratory syncytial virus (RSV), a
Pneumovirus within the Paramyxovirus family, determines host
cell tropism (Schendler et al., 2003), and recombinant RSV
particles lacking the G protein remained viable and able to
spread (Techaarpornkul et al., 2001).
In this study, an inhibitor of paramyxovirus fusion, fusion
inhibitory peptide (FIP) was used (Richardson and Choppin,
1983; Richardson et al., 1980). The tripeptide sequence of FIP
(Phe-Phe-Gly) is identical to the active site of the neurotrans-
mitter Substance P (Fig. 4A), which can also inhibit MV spread
in non-neuronal cultures (Harrowe et al., 1990; Schroeder,
1986). Substance P transduces signals to target cells by
engagement of the neurotachykinin family of G protein-coupled
neurotransmitter receptors, including neurokinin-1 (NK-1)
(Gerard et al., 1991; Schaffer et al., 1998), a highly conserved
protein expressed on diverse mammalian cells, including
neurons, lymphocytes, smooth muscle cells and vascular
endothelium (Pennefather et al., 2004). NK-1 expression is
not ubiquitous within the CNS, though most central structures
display some expression (Mantyh, 2002). In neurons, NK-1 is
broadly distributed on the plasma membrane, though concen-
trated at the synapse (Bozic et al., 1996). Here, we show that
both FIP and Substance P prevent MV spread in neurons and
that both genetic deletion and pharmacological inhibition of
NK-1 also reduce infection of permissive mice. Together, these
data indicate that fusion is a required step for viral transport
across the synaptic cleft and suggest that NK-1 plays a key role
in this process, perhaps serving as an MV-F receptor.Results
Expression and distribution of the fusion protein in
MV-infected primary neurons
We previously showed that inter-neuronal transmission of
MV was trans-synaptic and CD46-independent (Lawrence et
al., 2000). Because CD46-negative neurons were non-permis-
sive for infection by extracellular virus, but could support
infection when co-cultured with infected CD46+ neurons, we
hypothesized that the MV-H protein, though needed for initial
MV entry, may be dispensable for neuron-to-neuron trans-
synaptic spread of MV.
Because both MV-H and F are typically involved in viral
entry and spread, we next asked whether MV-F was translated
and processed in infected neurons. Lysates were prepared from
MV-infected or mock-infected neurons and Vero cells. Western
blots using a rabbit antibody raised against the F carboxy
terminus (Cathomen et al., 1998) were then performed on
protein lysates equivalent to 105 infected cells. For the mock-
infected controls, an amount of lysate corresponding to 105 cells
was used. MV-F is synthesized as a precursor (F0) that is post-
translationally cleaved into two subunits, F1 and F2. As shown
in Fig. 1, equivalent numbers of infected Vero fibroblasts and
CD46+ neurons yielded both F0 and F1 fragments, though the
amount of each present in neurons was consistently less.
Despite slight differences in expression levels, cleavage of the
F0 protein was efficient in both cell types. Note that the F2
fragment is not recognized by this antibody.
Fusion inhibitory peptide blocks MV spread in primary
neurons
Fusion inhibitory peptide (FIP) is a synthetic tripeptide (z-D-
Phe-L-Phe-Gly) that prevents fusion by multiple viruses,
though its strongest activity is against MV (Norrby, 1971;
Richardson and Choppin, 1983; Richardson et al., 1980). To
determine if FIP blocked MV spread in neurons, primary
neurons obtained from NSE-CD46+ embryonic hippocampi,
and control Vero fibroblasts were infected with MV-Ed using a
Table 1
The ability of FIP to prevent MV spread is dose-dependent a
FIP concentration (μM) MV infection (%) b
Veros Neurons
200 12 (±8) 4 (±3)
100 17 (±11) 9 (±5)
50 42 (±18) 14 (±4)
5 92 (±6) 15 (±5)
DMSO 87 (±11) 28 (±10)
a Veros and CD46+ primary neuron cultures were infected with MV-Ed at an
MOI=3. FIP (at the indicated concentrations) or the diluent, DMSO, was then
added 6 hpi, and cells were collected 2 dpi, immunostained and counted.
b Values represent the percent of infected cells per field, viewed at 100×
magnification, ±standard deviation. A total of 10 random fields were counted
from each of 3 independent experiments.
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post-infection (hpi). Cells were then collected 1–3 dpi and
immunostained for the presence of MV antigens. One
representative experiment of three using an MOI=0.1 and FIP
at 200 μM is shown in Fig. 2. In Vero cells without FIP, MV
spread rapidly, resulting in extensive infection and syncytia
(Fig. 2A). As expected, addition of FIP after infection prevented
viral spread and syncytia formation, and the monolayer
remained intact (Fig. 2B). Because FIP was added 6 hpi,
individual MV-positive cells were expected.
Similarly, addition of FIP after primary infection blocked the
trans-synaptic neuronal transmission of MV (Fig. 2D) that was
otherwise observed in untreated cultures (Fig. 2C). Identical
results were obtained when infection and FIP addition were
separated by 1 h, or when other MOIs were used (data not
shown). As shown in Table 1, the effect of FIP addition on MV
spread was dose-dependent for both cell types, with >50%
inhibition occurring at 50 μM. The inhibitory effect of FIP was
specific for MV as identical experiments with two other
neurotropic RNA viruses, lymphocytic choriomeningitis virus
(LCMV) and poliovirus (PV), showed no differences in
infection levels in the presence of FIP (data not shown).
FIP blocks MV infection of primary neurons
The initial characterization of paramyxovirus hydrophobic
fusion inhibitors showed that both de novo infection and
subsequent cell-to-cell spread were prevented (Norrby, 1971;
Richardson and Choppin, 1983; Richardson et al., 1980). In our
hands, however, addition of FIP prior to viral challenge did not
prevent infection of Vero cells (Fig. 3D), though subsequent
viral spread was blocked (Figs. 3E and F). The suppressive
effect of FIP was reversible: when FIP was washed out of the
cultures at 3 dpi, MV rebounded rapidly, resulting in the same
cytopathicity and syncytia formation as observed in untreatedFig. 2. Fusion inhibitory peptide prevents MV spread in primary neurons. Vero
cells and CD46+ neurons were plated onto coverslips as described and infected
with MV-Ed, MOI=0.1. Six hpi, FIP was added to achieve a final concentration
of 200 μM, and slips were fixed and immunostained 3 days thereafter. (A and B)
Vero cells; (C and D) neurons. (A and C) DMSO added; (B and D) FIP added.
Original magnification=400×. Shown are fields from one representative
experiment of three at this virus and dose concentration. No differences were
noted using MOIs ranging from 0.1 to 3.cultures (compare Figs. 3G and C). In contrast, pretreatment of
CD46+ neurons with FIP completely blocked infection (Figs.
3K–M), and, as expected, FIP washout did not result in MV re-
emergence (Fig. 3N). The inability of FIP to block infection of
Veros could be due to cell-specific differences in receptor
density, distribution (or utilization) of putative fusion receptors
(discussed below) or access of FIP to cell surfaces. Taken
together, these data indicate that FIP can prevent both infection
and spread in primary CD46+ mouse hippocampal neurons.
Inhibition of measles virus spread by neurotransmitters
The Phe-X-Gly sequence of FIP is also the active site of the
neurotachykinin family of peptide neurotransmitters that include
Substance P, Neurokinin A and Neurokinin B (Fig. 4A). For
Substance P, the central residue of the motif is a phenylalanine
(as in FIP), while for Neurokinin A and B it is a valine. In
addition, for FIP, the central Phe residue is the L-isomer, whereas
for the neurokinins, it is the D-isomer.
It was previously shown that Substance P could inhibit MV
spread in non-neuronal cultures (Harrowe et al., 1990;
Schroeder, 1986). To determine if the neurotachykinins block
MV trans-neuronal spread in our model system, we performed
inhibition experiments identical to those described above with
FIP, using the three neurotachykinins, two other non-neuro-
tachykinin peptide transmitters (bradykinin and opioid receptor
antagonist peptide) and a Substance P antagonist, spantide,
which does not contain the Phe-X-Gly motif. Peptides were
added at the indicated concentrations 6 hpi. Cells were collected
at 3 dpi and immunostained for MV. The number of infected
cells was expressed relative to DMSO treated cultures, which
were normalized to 100%. One representative experiment of
five is shown in Fig. 4B. Note that, as in Fig. 2, the neuro-
peptides were added after infection, so that some infected cells
were expected in all cultures. The infection baseline at 1 dpi is
indicated by the solid line, approximately 20%. For these
studies, virus yields were not used as a measure of activity as no
extracellular virus is released from infected primary neurons
(Lawrence et al., 2000).
All members of the neurotachykinin family inhibited MV
transmission in a dose-dependent manner, although Substance P
Fig. 3. FIP prevents de novo infection in neurons. Vero cells (A–G) and primary CD46+ neurons (H–N) were plated on coverslips as described. FIP (200 μM) (D–G;
K–N), or an equivalent volume of DMSO (A–C; H–J) were added and, after a 1 h incubation, cells were infected with MV-Ed, MOI=3. Coverslips were fixed and
immunostained 1–3 dpi. For the washout experiments (G and N), at 3 dpi the cells were washed and replaced with fresh media without FIP. Samples were then
collected 48 h post-FIP removal, equivalent to 5 dpi. Representative fields from one of four independent experiments are shown. Original magnification=100×.
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concentrations (Fig. 4B, and data not shown). Non-neurotachy-
kinin peptides had no effect on MV transmission. Moreover,
spantide, a Substance P antagonist that lacked the Phe-Phe-Gly
motif and that presumably does not bind to the same site on NK-
1 as Substance P, also had no effect on MV spread, underscoring
the potential importance of this motif in MV-mediated fusion.
The Substance P receptor, neurokinin-1, contributes to MV
trans-neuronal spread
We next asked if the cellular receptors for the neurotachy-
kinin peptides were required for MV spread, with particular
emphasis on NK-1, the predominant Substance P receptor. Two
strategies were used: genetic knockout mice (Fig. 5) and
pharmacological NK-1 inhibitors (Fig. 6).
NK-1 knockout (NK-1 KO) mice (Bozic et al., 1996) were
intercrossed with NSE-CD46+ homozygous mice to obtain NSE-
CD46+/NK-1 KO mice. As reported in the original characteriza-
tion, NK-1 KO mice show no apparent developmental abnorm-
alities with regard to lifespan, fertility, fecundity or brain anatomy
(Bozic et al., 1996). All micewere genotyped for CD46 and NK-1
status, as described in Materials and methods. Because neonatal
CD46+ mice (that are also NK-1+) succumb to MV-mediated
CNS disease following viral challenge (Lawrence et al., 1999;
Rall et al., 1997), we asked what impact genetic deletion of NK-1
would have onMV neuronal infection and resultant pathogenesisin the neonatal model. As previously shown,MV-infected control
CD46+/NK-1+ neonates (black triangles) developed symptoms
within 4–8 dpi and died 1–2 days thereafter (Fig. 5A). In contrast,
CD46+/NK-1 KO neonates (black circles) either showed no signs
of illness through adulthood, or developed illness at a much later
time (18 dpi in 35% of CD46+/NK-1 KO neonates vs. 5–9 dpi in
100% of CD46+/NK-1+ neonates) (Fig. 5A). None of the
surviving CD46+/NK-1 KO mice showed evidence of MV CNS
infection by RT-PCR analysis; in contrast, MV antigens were
observed in all moribund CD46+/NK-1 KO mice collected at 18
dpi (data not shown). As expected, CD46−/NK-1+ mice (white
circles) were non-permissive for infection and showed no signs of
illness or infection at any timepoint, indicating that NK-1 alone
cannot mediate MVentry.
To ascertain the extent of MV infection in NK-1 expressing
and non-expressing neonates collected at the same timepoint
post-infection, neonatal CD46+/NK-1+ and CD46+/NK-1 KO
mice were challenged as described, and brains from all mice
were collected 6 dpi, the approximate peak of infection within
the CNS (Lawrence et al., 1999). Detection of the MV-N gene
by RT-PCR analysis of total brain RNA showed evidence of
replication in 4/4 (100%) CD46+/NK-1+ mice, whereas only
2/11 (18%) CD46+/NK-1 KO mice were positive (Fig. 5B).
These data suggest that, even when CD46 is present,
expression of NK-1 is required for infection in the majority
of mice. However, while NK-1 influences both the number of
mice infected and the kinetics of infection, it is not obligatory
Fig. 4. Effect of neuropeptide transmitters on MV spread. (A) Amino acid sequences of neuropeptides used. Gray boxes indicate active sites of the neurotachykinins
and homology with FIP. (B) Inhibitory effect of each neuropeptide on MV spread. Neurons were infected with MV-Ed, and neuropeptides were added to a final
concentration of 200 μM; for Substance P, three doses were tested: 200, 100 and 50 μM. Samples were collected 3 dpi and counted; values reflect the percent infection
as compared with the DMSO control. The horizontal line indicates the initial level of infection after∼1 round of replication (24 hpi). Because the peptides were added
after infection, this represents the maximal achievable inhibitory effect. Shown is one representative experiment of five.
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neuropathogenesis.
As an alternative strategy to ascertain what role NK-1
played in MV infection of neurons, the high-affinity pharma-
cological NK-1 antagonist, aprepitant, currently used clini-
cally as an anti-emetic (Emend®), was employed. Unlike the
genetic knockout studies described above, neonates could not
be used for the aprepitant studies because of the technical
obstacle of oral drug delivery to neonatal mice. Thus, CD46+
adult mice on a RAG-2 KO background were used: these
mice, which lack mature T and B cells, cannot resolve a MV
challenge and virtually 100% become moribund between 10
and 14 dpi (Lawrence et al., 1999). As shown in Fig. 6A, all
MV-inoculated CD46+/RAG-2 KO mice that did not receive
aprepitant showed an average weight loss of 15% and anaverage illness score of 3.4 (obtained between day 6 and 10)
prior to sacrifice. In contrast, aprepitant-treated CD46+/RAG-
2 KO mice segregated into two populations: those that
developed neuropathology, and those that did not. In the
representative experiment shown, 14/25 mice developed a
milder illness than non-aprepitant-treated controls (2.1 vs.
3.4), and weight loss in these mice was less, averaging 5%.
Importantly, 11/25 MV-challenged mice treated with aprepi-
tant showed no signs of illness or weight loss. RT-PCR
analysis of purified total brain RNA confirmed the absence of
MV-N RNA in brains of healthy aprepitant-treated mice (data
not shown).
When brains were collected from aprepitant-treated and
untreated, MV-infected CD46+/RAG-2 KO mice between 10
and 12 dpi and immunostained, mice without aprepitant showed
Fig. 5. Infection in neurokinin-1 knockout neonatal mice. (A) Survival curves
following MV challenge in CD46+/NK-1+ neonates (black triangles, n=11);
CD46−/NK-1+ neonates (white circles, n=20); and CD46+/NK-1 KO neonates
(black circles, n=12). Shown is one representative experiment of three. NSE-
CD46+ neonates were chosen because these mice are permissive for MV
infection and develop CNS disease within 1 week post-challenge (Lawrence et
al., 1999). (B) RT-PCR analysis for MV-nucleoprotein of total brain RNA,
harvested from neonatal CD46+/NK-1+ and CD46+/NK-1 KO mice at 6 dpi with
MV-Ed, as described in Materials and methods.
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(Fig. 6B(a–c)), whereas sick mice that were treated with
aprepitant had less viral infection that seemed to be more
focally restricted within the parenchyma (Fig. 6B(d–f)). No
evidence of MV infection within the CNS was observed in
healthy mice that received aprepitant (Fig. 6B(g–i)). Taken
together, the results from both the drug and knockout
experiments indicate that NK-1, a receptor for the neurotrans-
mitter Substance P, plays a crucial role in MV spread. We
hypothesize that NK-1 may be a docking receptor for the MV-F
protein, facilitating cell-to-cell MV transmission.
Discussion
Our previous studies demonstrated that the mechanism of
MV transmission in neurons differed dramatically from that in
non-neuronal cells (Lawrence et al., 2000). In fibroblasts, MV
was highly cytolytic and resulted in robust release of
infectious particles. In contrast, no virus-mediated lysis of
infected primary hippocampal neurons was detected, nor
could extracellular virus be recovered, despite extensive viral
replication and spread. Electron microscopy studies revealed
both a block in the ability of MV to bud from the neuronal
plasma membrane as well as the presence of viral RNPs at
synaptic junctions, indicating that MV adopts a trans-synaptic
mode of spread in neurons (Lawrence et al., 2000).
Interestingly, trans-synaptic transmission was CD46-indepen-
dent, a characteristic that appears to be unique to neurons, as
CD46 was required for viral spread in fibroblast co-cultures
(Makhortova et al., manuscript in press).A synthetic tripeptide, FIP, that blocks MV fusion (Norrby,
1971; Payan et al., 1984; Richardson and Choppin, 1983),
inhibited both MV infection and spread in primary neurons
expressing one of the human receptors, CD46. The mechanism
by which FIP prevents fusion is not known, but may either be
due to direct interference of the amino terminus of the F1
subunit with the target cell membrane, or to preventing the
exposure of the fusogenic peptide (Norrby, 1971; Richardson
and Choppin, 1983; Kelsey et al., 1991).
The similarity of sequence between FIP and the neuro-
transmitter Substance P, coupled with previous reports that
Substance P could interfere with MV replication in non-
neuronal cells (Schroeder, 1986; Richardson et al., 1980),
prompted us to ask whether Substance P and other members of
the neurotachykinin family could prevent viral translocation
across the synaptic cleft. Indeed, all neurotachykinins blocked
spread, a process that appeared to depend, at least in part, on the
presence of the neurotachykinin receptor, NK-1. The majority
of NK-1 deficient neonates, as well as NK-1+ adults mice
treated with the specific antagonist, aprepitant, survived viral
challenge without any symptoms of disease or viral replication
in the CNS. Thus, we speculate that NK-1 may promote MV
entry into CD46+ neurons by serving as a docking receptor for
the MV-F protein and that the ability of FIP and Substance P to
block infection and spread may be due to competitive inhibition
with the NK-1 receptor, a hypothesis currently under study in
our laboratory.
The apparent ability of NK-1 to mediate viral spread at the
neuronal synapse in the absence of an H receptor may be a
unique attribute of this specialized membrane. MV-Ed trans-
synaptic spread can occur in the absence of CD46, and primary
mouse neurons do not express the other identified MV receptor,
SLAM/CD150w. While these data indicate that trans-synaptic
spread may not require a receptor for the H protein, we cannot
rule out the possibility that a protein expressed at the post-
synaptic membrane may serve as a unique H-receptor in neu-
rons, specifically facilitating neuron-to-neuron transport across
synapses. However, given the similarity in sequence and
activity of Substance P and the fusion inhibitor FIP, we favor
the idea that F, through binding to neurokinin receptors,
facilitates transport of MV RNPs across the synapse in the
absence of a need for H. Importantly, NK-1 is expressed in all
mammals and on virtually all cells, including the Vero
fibroblasts used as controls in our experiments (data not
shown). Thus, we are also currently testing whether NK-1 is a
necessary co-factor for MV entry into all permissive cells.
Moreover, given that these studies were performed with MV-
Edmonston, a vaccine strain, it will be important to address
what role NK-1 plays in entry and spread of wild type isolates.
While our data implicate an important role for NK-1 in
MV spread in neurons, some infected mice with deleted or
impaired NK-1 did become infected, and neither FIP nor
Substance P was able to fully ablate MV spread in primary
neurons. This inability could be explained by: a) an
insufficient concentration of these inhibitors at the synaptic
membrane; b) a rapid off-rate of Substance P from NK-1
(Sarntinoranont et al., 2003); and/or c) the potential for MV-F
Fig. 6. Weight loss, morbidity and MV infection levels in untreated and aprepitant-treated NSE-CD46+/RAG-2 KO mice. (A) Mice were infected as described and
administered aprepitant orally 1 day prior to infection (double dose), 1 day after infection, and every other day thereafter. Mice were monitored daily and scored from 0
to 4, based on the defined criteria (see Materials and methods). Average values (obtained between days 6 and 10) are shown. Mice were also weighed on the day before
infection to establish individual baselines, and every other day thereafter. Maximal weight changes are shown as percent weight loss or gain. (B) Mice were infected as
described and collected between 10 and 12 days post-infection. Shown are immunohistochemical results from untreated (a–c) and aprepitant-treated (d–i) mice. (d–f)
Sick animals at collection; (g–i) healthy animals at collection. Original magnification=20×.
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NK-3, for entry. Because all three neurotachykinins inhibited
MV spread to some degree (Fig. 4B), and each serves as the
ligand for three different neurokinin receptors, it remains
possible that the other neurokinin receptors, NK-2 and NK-3,
may serve as surrogates for MV entry under circumstances in
which NK-1 is not present or active.
A recent paper provides additional support for the fusion–
tachykinin relationship. The F protein of bovine respiratory
syncytial virus (BRSV), a member of the Paramyxovirus family,is post-translationally cleaved twice, unlike MV-F, which is
cleaved once. The small peptide that is released from BRSV-F
cleavage is converted to a biologically active tachykinin, called
virokinin (Zimmer et al., 2003). This soluble, virus-encoded
peptide interacts with NK-1 and triggers the same downstream
pathways as the bona fide ligand, Substance P. Thus, fusion
proteins or post-translationally cleaved products derived from
the fusion proteins of multiple Paramyxoviruses appear to
interact with neurokinin receptors, though the benefit such an
interaction confers to the virus is not yet understood.
242 N.R. Makhortova et al. / Virology 362 (2007) 235–244Finally, these data may have implications for MV pathogen-
esis in the CNS. In the NSE-CD46 mouse model of neuronal
MV infection, CNS disease occurs in infected, immunodeficient
animals in the absence of neuronal death (Patterson et al., 2002),
suggesting that CNS disease in this mouse model is due to
neuronal dysfunction rather than overt cell loss. We hypothesize
that MV-mediated fusion of neuronal synapses could promote
neuropathology through a number of possible mechanisms,
including constitutive neurotransmitter signaling or loss of
synaptic integrity. Continued use of this model system will
allow us to determine how receptor interactions may contribute
to neuropathology and may identify novel candidates for
antiviral therapies to prevent or limit MV-induced neuropathol-
ogy in humans.
Materials and methods
Cells and virus
Vero fibroblasts were maintained in Dulbecco's modified
Eagle medium (DMEM) (Life Technologies), supplemented
with 10% fetal calf serum (FCS), 2 mM glutamine, 100 U/ml
penicillin, and 100 ng/ml streptomycin. Primary hippocampal
neurons were prepared from day e15–e16 embryonic mice, as
described (Banker and Goslin, 1991; Pasick et al., 1994; Rall et
al., 1995), except that the cells were maintained in Neurobasal
medium (Life Technologies), containing 4 μg/ml glutamate, in
the absence of an astrocyte feeder layer. All neurons were
obtained from NSE-CD46+ embryonic brain tissues, except for
the control poliovirus study, in which neurons were isolated
from PVR+ transgenic mice (a gift from Raul Andino, UCSF).
All cells were maintained at 37 °C in a humidified incubator
with 5% CO2.
Measles virus (MV; Edmonston strain) was purchased from
American Type Cell Collection (ATCC) and was passaged and
titered in Vero fibroblasts, as was poliovirus (PV; Mahoney
strain), a gift from Luis Sigal (Fox Chase Cancer Center).
Lymphocytic choriomeningitis virus (LCMV; Armstrong
strain), a gift from Michael Oldstone (The Scripps Research
Institute, La Jolla, CA), was passaged on BHK-21 fibroblasts
and titered on Vero fibroblasts.
Western blot analysis
Hippocampal neurons were plated onto poly-lysine coated
6-well tissue culture dishes and were infected 72 h post-
plating with MV-Ed at a multiplicity of infection (MOI)=
0.1–3. Vero fibroblasts (4 h post-plating) were infected
identically. Three days later, infected and mock-infected cell
lysates were collected by scraping cells in 1× protein buffer,
followed by a 20 s sonication. Samples were stored at −70 °C
and boiled for 5 min prior to loading. Proteins were separated
using 8% SDS–PAGE and transferred to a nylon membrane.
Rabbit polyclonal antiserum directed against the MV-F
cytoplasmic tail (a gift from Roberto Cattaneo, Mayo Clinic,
Rochester, MN; (Cathomen et al., 1998)) was used as the
primary antibody (diluted 1:1000 in 10% milk) followed byincubation with a peroxidase-conjugated anti-rabbit IgG sec-
ondary antibody (diluted 1:2000; Vector Laboratories). Bands
were visualized using chemiluminescence (ECL; Dupont NEN).
Immunohistochemistry
Coverslip-bound cells or cryosectioned, 10 μm-thick hor-
izontal brain sections were fixed with ice-cold methanol/acetone
(1:1) for 10 min, dried and rehydrated in PBS. Samples were
blocked with 1% (vol/vol) normal goat serum in PBS, followed
by avidin and biotin blocking (Vector Laboratories). A human
antiserum (Keller, a gift from Michael Oldstone) was used at a
dilution of 1:2000. Appropriate secondary antibodies conju-
gated to biotin were used at a 1:300 dilution. A streptavidin–
peroxidase conjugate (ABC Elite; Vector) was then added
followed by visualization with diaminobenzidene (DAB;
0.7 mg/ml in 60 mM Tris; Sigma) and H2O2 (1.6 mg/ml).
Cells and sections were counterstained with hematoxylin and
mounted with an aqueous mounting medium. As controls,
uninfected cells or brains, samples from which the primary
antibody was omitted, or samples using an irrelevant, isotype-
matched primary antibody were included.
Inhibitor studies in cell culture
To determine the impact of various reagents on viral
infection, primary neurons or control Vero cells were first
treated with the reagents at the indicated concentrations for 1 h
followed by infection in the presence of the putative inhibitor.
Following a 1 h incubation with virus, the inoculum was
removed, and the cells were gently washed with warmed PBS
(pH 7.4). Thereafter, the appropriate medium, containing fresh
inhibitor, was added. Coverslips were then fixed at the indicated
day post-infection (dpi).
To explore the impact of these reagents on viral spread, the
process was reversed: cells were infected for either 1 or 6 h
followed by addition of the reagents thereafter at the indicated
concentrations. All reagents were obtained from Bachem and
were dissolved in DMSO or 1 N acetic acid. Reagents used
include the following: fusion inhibitory peptide (FIP; z-D-Phe-L-
Phe-Gly-OH); the neurotachykinins Substance P (H-Arg-Pro-
Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2), neurokinin A
(H-His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NH2) and
neurokinin B (H-Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-
Met-NH2); bradykinin (H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-
Arg-OH); the opioid receptor antagonist, H-Tyr-L-1,2,3,4-
tetrahydroisoquinoline-3-carboxamide (H-Tyr-Tic-NH2); and
the Substance P antagonist, spantide (H-D-Arg-Pro-Lys-Pro-
Gln-Gln-D-Trp-Phe-D-Trp-Leu-Leu-NH2). Control cultures
were incubated with an equivalent volume of DMSO or
1 N acetic acid and coverslips were harvested and stained for
MV as indicated above.
Challenge experiments in mice
Adult mice between 6 and 10 weeks of age and neonatal
mice between 2 and 3 days of age were used. Neurokinin-1
243N.R. Makhortova et al. / Virology 362 (2007) 235–244knockout (KO) mice (H-2b) were obtained from Norma Gerard
(Harvard University) (Bozic et al., 1996) and intercrossed for 8
generations with NSE-CD46 transgenic mice (H-2b). For all
mice, genotype verification for CD46, NK-1 and haplotype was
performed on DNA isolated from tail biopsies or on blood
samples collected from the retro-orbital sinus. To confirm CD46
status, standard PCR (30 cycles) was performed using the
following primers: upstream: CGGTC GCTAC CATTA
CCAGT; downstream: CCCCC TGAAC CTGAA ACATA.
To confirm NK-1 KO status, two primer pairs were used, one
pair to verify the absence of the targeted region of the NK-1
gene (upstream: TTGAG TCCTG CTACT CAGGA; down-
stream: ACTTT TACTA GCTGC GCTGC), and the other to
confirm the presence of the neomycin resistance gene (up-
stream: TCAGC GCAGG GGCGC CCGGT TCTTT; down-
stream: ATCGA CAAGA CCGGC TTCCA TCCGA).
Neonatal CD46+/NK-1 KO mice (less than 3 days of age)
were challenged intracerebrally with 104 PFUMV-Ed, delivered
in a volume of 10 μl along the midline using a 27-gauge needle.
Infected pups were monitored daily, and animals showing signs
of virus-induced illness (maternal rejection, absence of weight
gain) were euthanized.
For the aprepitant (Emend®, Merck Pharmaceuticals)
studies in adult mice, the same dose recommended for humans
(80 mg/kg), adjusted for body weight, was given to adult
CD46+ mice on a RAG-2 KO background (Lawrence et al.,
1999). The drug was suspended in PBS and delivered in a
volume of 200 μl via oral gavage every other day following
viral challenge. The day prior to infection, a double dose of the
drug was administered. Animal health was monitored daily, and
mice were weighed and assessed every other day following
viral challenge. For the health assessment, mice were scored
based on the following subjective scale: 0=healthy; 1=slight
ruffling, hunching, or lack of mobility; 2=any two of these
symptoms or severe appearance of one; 3=all three symptoms,
or severe incidence of two; 4=moribund. All mouse experi-
ments were reviewed and approved by the Fox Chase Cancer
Center IACUC.
Tissue harvesting, histology and RNA isolation and analysis
From some mice, brain tissues were collected for either IHC
or RNA analysis. For IHC studies, tissues were immersed in
OCT embedding compound, quick-frozen in a dry ice/
isopentane bath and stored at −80 °C. Thereafter, 10 μm
cryosections were obtained and stored at −80 °C. Sections were
thawed, fixed in ice-cold 95% ethanol and immunostained as
described above.
To isolate RNA from infected tissues, brains were snap-
frozen in liquid nitrogen and homogenized in TriReagent
(Sigma). Thereafter, RNAwas purified and quality-tested by gel
electrophoresis. RNA was then subjected to RT-PCR using
SuperScript II reverse transcriptase (Invitrogen) followed by
amplification using MV-specific primers for nucleoprotein
(upstream: ACTTA GGAGC AAAGT GATTG CCT; down-
stream: AACAA CACGG AACCT CTGCG G). Amplicons
were visualized by electrophoresis on a 1.5% agarose gel.Acknowledgments
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